Journal of Movement Disorders

Brief communication

COVID-19 vaccine related movement disorders: a systematic review: Grace Elysse D. Angeles, Lowrence Precious C. Dichoso, Roland Dominic G. Jamora; Received January 2, 2024 Accepted March 18, 2024 Published online March 19, 2024; DOI: https://doi.org/10.14802/jmd.24001 [Accepted]

498 View
31 Download
1 Comments

Abstract PDF: Objectives
Since the release of vaccines against COVID-19, there have been reports of vaccine-related neurologic complications. This study aimed to create a descriptive systematic review of movement disorders associated with COVID-19 vaccines.
Methods
We described the demographics, clinical presentation, management, outcomes, and proposed patho-mechanism. A systematic review was performed according to the PRISMA guidelines. A standardized tool was used to assess the quality of the cases.
Results
We have identified 8 articles that met our inclusion criteria consisting of 10 patients who developed movement disorders after vaccination. The majority were males (n = 8), with a median age of 64.5 years. The most common movement disorder was hemichorea. The rest presented with generalized chorea with myoclonus, cervical dystonia, and akathisia. Most cases responded with immunotherapy. The standardized tool used showed that most studies have a low risk of bias.
Conclusion
The reported incidence of vaccine-related movement disorders was low in occurrence based on available published cases that were found.

Review Articles

Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy: Smriti Sinha, Swati Mittal, Rupali Roy; J Mov Disord. 2021;14(3):184-192. Published online July 29, 2021; DOI: https://doi.org/10.14802/jmd.21046

6,617 View
217 Download
12 Web of Science
13 Crossref

There is an extensive debate on the neurological consequences of 2019 novel coronavirus disease (COVID-19) and its impact on Parkinson’s disease (PD) patients, which seems to puzzle neurologists. Links between viral infections and PD have long been suspected and studied, but the exact relationship remains elusive. Since severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) enters the brain through multiple routes and has a direct impact on the brain, cumulative damage occurs due to the activation of proinflammatory cytokines and chemokines. SARS-CoV-2 seems to aggravate PD due to its effects on α-synuclein, mitochondrial dysfunction, and dopamine depletion. A few studies have even highlighted the higher vulnerability of PD patients to COVID-19. The sudden dramatic change in lifestyle caused by the pandemic and the widespread lockdowns that were implemented have added to the hidden sorrows of PD patients, as they already have a compromised mechanism for coping with stress. This review summarizes insights from basic science and the clinical effect of SARS-CoV-2 infection on the human brain, with a specific focus on PD.

Citations

Citations to this article as recorded by

Assessment of the relationship between the dopaminergic pathway and severe acute respiratory syndrome coronavirus 2 infection, with related neuropathological features, and potential therapeutic approaches in COVID‐19 infection
Yousef Rasmi, Ameneh Shokati, Shima Hatamkhani, Yeganeh Farnamian, Roya Naderi, Ladan Jalali
Reviews in Medical Virology.2024;[Epub] CrossRef
SARS-CoV-2 Infection to Premature Neuronal Aging and Neurodegenerative Diseases: Is there any Connection with Hypoxia?
Narmadhaa Sivagurunathan, Latchoumycandane Calivarathan
CNS & Neurological Disorders - Drug Targets.2024; 23(4): 431. CrossRef
Deciphering the molecular pathways underlying dopaminergic neuronal damage in Parkinson's disease associated with SARS-CoV-2 infection
Qiuhan Xu, Sisi Jiang, Ruiqing Kang, Yiling Wang, Baorong Zhang, Jun Tian
Computers in Biology and Medicine.2024; 171: 108200. CrossRef
Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson’s Disease
Valentina Fioravanti, Francesco Cavallieri, Alessio Di Fonzo, Giulia Toschi, Sara Grisanti, Gaetano Salomone, Mario Zappia, Franco Valzania
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2023; 50(5): 777. CrossRef
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms
Pei Huang, Lin-Yuan Zhang, Yu-Yan Tan, Sheng-Di Chen
Translational Neurodegeneration.2023;[Epub] CrossRef
Does the SARS-CoV-2 Spike Receptor-Binding Domain Hamper the Amyloid Transformation of Alpha-Synuclein after All?
Yulia Stroylova, Anastasiia Konstantinova, Victor Stroylov, Ivan Katrukha, Fedor Rozov, Vladimir Muronetz
Biomedicines.2023; 11(2): 498. CrossRef
Sex and age affect acute and persisting COVID-19 illness
Anna Vasilevskaya, Asma Mushtaque, Michelle Y. Tsang, Batoul Alwazan, Margaret Herridge, Angela M. Cheung, Maria Carmela Tartaglia
Scientific Reports.2023;[Epub] CrossRef
Vulnerability of Parkinson’s Patients to COVID-19 and Its Consequences and Effects on Them: A Systematic Review
Sorayya Rezayi, Meysam Rahmani Katigari, Leila Shahmoradi, Mehrbakhsh Nilashi, Hélio Teive
Parkinson's Disease.2023; 2023: 1. CrossRef
COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent
Sebastián García Menéndez, Virna Margarita Martín Giménez, Michael F. Holick, Francisco J. Barrantes, Walter Manucha
Life Sciences.2022; 297: 120464. CrossRef
SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro
Zhengcun Wu, Xiuao Zhang, Zhangqiong Huang, Kaili Ma
International Journal of Molecular Sciences.2022; 23(6): 3394. CrossRef
COVID-19 and Parkinsonism: A Critical Appraisal
Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
Biomolecules.2022; 12(7): 970. CrossRef
SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response
Pi-Ching Hsu, Md. Shahed-Al-Mahmud
Life Sciences.2022; 308: 120981. CrossRef
COVID-19 і хвороба Паркінсона
I.M. Karaban, T.V. Hasiuk, N.V. Karasevych
INTERNATIONAL NEUROLOGICAL JOURNAL.2022; 18(3): 46. CrossRef

Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination: Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim; J Mov Disord. 2021;14(3):177-183. Published online July 29, 2021; DOI: https://doi.org/10.14802/jmd.21034

6,472 View
156 Download
9 Web of Science
6 Crossref

Abstract PDF

The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has led to a serious global health crisis. Increasing evidence suggests that elderly individuals with underlying chronic diseases, including Parkinson’s disease (PD), are particularly vulnerable to this infection. Changes in the routine care of PD patients should be implemented carefully without affecting the quality provided. The utilization of telemedicine for clinical consultation, assessment and rehabilitation has also been widely recommended. Therefore, the aim of this review is to provide recommendations in the management of PD during the pandemic as well as in the early phase of vaccination programs to highlight the potential sequelae and future perspectives of vaccination and further research in PD. Even though a year has passed since COVID- 19 emerged, most of us are still facing great challenges in providing a continuum of care to patients with chronic neurological disorders. However, we should regard this health crisis as an opportunity to change our routine approach in managing PD patients and learn more about the impact of SARS-CoV-2. Hopefully, PD patients can be vaccinated promptly, and more detailed research related to PD in COVID-19 can still be carried out.

Citations

Citations to this article as recorded by

Increasing exercise with a mobile app in people with Parkinson’s disease: a pilot study
Jong Hyeon Ahn, Dongrul Shin, Dongyeong Lee, Hye Young Kim, Jinyoung Youn, Jin Whan Cho, Suzanne Kuys
Brain Impairment.2024;[Epub] CrossRef
A large survey on COVID-19 vaccination in patients with Parkinson’s disease and healthy population
Chao Han, Zhen Zhen Zhao, Piu Chan, Fang Li, Chun Ling Chi, Xin Zhang, Yan Zhao, Jing Chen, Jing Hong Ma
Vaccine.2023; 41(43): 6483. CrossRef
Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
Jeremy M. Morowitz, Kaylyn B. Pogson, Daniel A. Roque, Frank C. Church
Brain Sciences.2022; 12(5): 536. CrossRef
Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review
Jasjit S. Suri, Mahesh A. Maindarkar, Sudip Paul, Puneet Ahluwalia, Mrinalini Bhagawati, Luca Saba, Gavino Faa, Sanjay Saxena, Inder M. Singh, Paramjit S. Chadha, Monika Turk, Amer Johri, Narendra N. Khanna, Klaudija Viskovic, Sofia Mavrogeni, John R. Lai
Diagnostics.2022; 12(7): 1543. CrossRef
Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease
Sabrina Poonja, K. Ray Chaudhuri, Janis M. Miyasaki
Current Opinion in Neurology.2022; 35(4): 494. CrossRef
Viruses, parkinsonism and Parkinson’s disease: the past, present and future
Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau, Donna Mathew, Iro Boura, Vanessa Raeder, Cristian Falup-Pecurariu, Daniel van Wamelen, K. Ray Chaudhuri
Journal of Neural Transmission.2022; 129(9): 1119. CrossRef

Case Report

Myoclonus-Ataxia Syndrome Associated with COVID-19: Kuldeep Shetty, Atul Manchakrao Jadhav, Ranjith Jayanthakumar, Seema Jamwal, Tejaswini Shanubhogue, Mallepalli Prabhakar Reddy, Gopal Krishna Dash, Radhika Manohar, Vivek Jacob Philip, Vikram Huded; J Mov Disord. 2021;14(2):153-156. Published online April 6, 2021; DOI: https://doi.org/10.14802/jmd.20106

7,506 View
188 Download
9 Web of Science
8 Crossref

Abstract PDF Supplementary Material

Neurological manifestations of coronavirus disease (COVID-19) have increasingly been reported since the onset of the pandemic. Herein, we report a relatively new presentation. A patient in the convalescence period following a febrile illness with lower respiratory tract infection (fever, myalgia, nonproductive cough) presented with generalized disabling myoclonus, which is phenotypically suggestive of brainstem origin, along with additional truncal cerebellar ataxia. His neurology work-ups, such as brain MRI, electroencephalography, serum autoimmune and paraneoplastic antibody testing, were normal. His CT chest scan revealed right lower lung infiltrates, and serological and other laboratory testing did not show evidence of active infection. COVID-19 titers turned out to be strongly positive, suggestive of post-COVID-19 lung sequelae. He responded partially to antimyoclonic drugs and fully to a course of steroids, suggesting a para- or postinfectious immune-mediated pathophysiology. Myoclonusataxia syndrome appears to be a neurological manifestation of COVID-19 infection, and knowledge regarding this phenomenon should be increased among clinicians for better patient care in a pandemic situation.

Citations

Citations to this article as recorded by

Opsoclonus Myoclonus Ataxia Syndrome Due to SARS-CoV-2
Josef Finsterer, Fulvio A. Scorza
Neuro-Ophthalmology.2023; 47(1): 1. CrossRef
Myoclonus in patients with COVID‐19: Findings of autoantibodies against brain structures in cerebrospinal fluid
Isa Lindqvist, Janet L. Cunningham, Jan Mulder, Amalia Feresiadou, Elham Rostami, Johan Virhammar, Eva Kumlien
European Journal of Neurology.2023; 30(10): 3142. CrossRef
Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19
Kenta Osawa, Atsuhiko Sugiyama, Akiyuki Uzawa, Shigeki Hirano, Tatsuya Yamamoto, Masahiko Nezu, Nobuyuki Araki, Hiroki Kano, Satoshi Kuwabara
Internal Medicine.2022; 61(7): 1071. CrossRef
Post‐infectious cerebellar ataxia following COVID‐19 in a patient with epilepsy
Sidhartha Chattopadhyay, Judhajit Sengupta, Sagar Basu
Clinical and Experimental Neuroimmunology.2022; 13(4): 323. CrossRef
Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis
Rizaldy Taslim Pinzon, Vincent Ongko Wijaya, Abraham Al Jody, Patrick Nalla Nunsio, Ranbebasa Bijak Buana
Journal of Infection and Public Health.2022; 15(8): 856. CrossRef
Anti-neuronal antibodies against brainstem antigens are associated with COVID-19
Guglielmo Lucchese, Antje Vogelgesang, Fabian Boesl, Dina Raafat, Silva Holtfreter, Barbara M. Bröker, Angela Stufano, Robert Fleischmann, Harald Prüss, Christiana Franke, Agnes Flöel
eBioMedicine.2022; 83: 104211. CrossRef
Post–COVID‐19 Myoclonus–Ataxia Syndrome Responsive to Intravenous Immunoglobulins
Massimiliano Godani, Alessandro Beronio, Giuseppe Lanza
Movement Disorders Clinical Practice.2022;[Epub] CrossRef
Anti-GAD associated post-infectious cerebellitis after COVID-19 infection
Ahmed Serkan Emekli, Asuman Parlak, Nejla Yılmaz Göcen, Murat Kürtüncü
Neurological Sciences.2021; 42(10): 3995. CrossRef

Original Article

Telemedicine in an Academic Movement Disorders Center during COVID-19: Christine Doss Esper, Laura Scorr, Sosi Papazian, Daniel Bartholomew, Gregory Jacob Esper, Stewart Alan Factor; J Mov Disord. 2021;14(2):119-125. Published online March 18, 2021; DOI: https://doi.org/10.14802/jmd.20099

6,379 View
146 Download
13 Web of Science
14 Crossref

Abstract PDF

Objective
Telemedicine has rapidly gained momentum in movement disorder neurology during the coronavirus disease (COVID-19) pandemic to preserve clinical care while mitigating the risks of in-person visits. We present data from the rapid implementation of virtual visits in a large, academic, movement disorder practice during the COVID-19 pandemic.
Methods
We describe the strategic shift to virtual visits and retrospectively examine elements that impacted the ability to switch to telemedicine visits using historical prepandemic in-person data as a comparator, including demographics, distance driven, and diagnosis distribution, with an additional focus on patients with deep brain stimulators.
Results
A total of 686 telemedicine visits were performed over a five-week period (60% of those previously scheduled for in-office visits). The average age of participants was 65 years, 45% were female, and 73% were Caucasian. Men were more likely to make the transition (p = 0.02). Telemedicine patients lived farther from the clinic than those seen in person (66.47 km vs. 42.16 km, p < 0.001), age was not associated with making the switch, and patient satisfaction did not change. There was a significant shift in the distribution of movement disorder diagnoses seen by telemedicine compared to prepandemic in-person visits (p < 0.001). Patients with deep brain stimulators were more likely to use telemedicine (11.5% vs. 7%, p < 0.001).
Conclusion
Telemedicine is feasible, viable and relevant in the care of movement disorder patients, although health care disparities appear evident for women and minorities. Patients with deep brain stimulators preferred telemedicine in our study. Further study is warranted to explore these findings.

Citations

Citations to this article as recorded by

The Importance of Digital Health Literacy in an Evolving Parkinson’s Disease Care System
Christine D. Esper, Blanca Y. Valdovinos, Ruth B. Schneider
Journal of Parkinson's Disease.2024; : 1. CrossRef
Long‐Lasting Impact of the COVID‐19 Pandemic on Patients with Parkinson's Disease and Their Relatives
Andreas Wolfgang Wolff, Bernhard Haller, Antonia Franziska Demleitner, Dominik Pürner, Johanna Niederschweiberer, Isabell Cordts, Erica Westenberg, Paul Lingor
Movement Disorders Clinical Practice.2023; 10(5): 819. CrossRef
Telemedicine technologies and applications in the era of COVID-19 pandemic: A systematic review
Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi, Mohammad Heydari, Amirali Karimi, Abdollah Mahdavi, Mehrnaz Mashoufi, Arezoo Sarmad, Peyman Mirghaderi, Ahmadreza Shamsabadi, Kowsar Qaderi, Pegah Mirzapour, Amirata Fakhfouri, Hadiseh Azadi Cheshmekabodi, Kimia
Health Informatics Journal.2023; 29(2): 146045822311674. CrossRef
Racial disparities in access to DBS: results of a real-world U.S. claims data analysis
Michael Frassica, Drew S. Kern, Mitra Afshari, Allison T. Connolly, Chengyuan Wu, Nathan Rowland, Juan Ramirez-Castaneda, Mwiza Ushe, Claudia Salazar, Xenos Mason
Frontiers in Neurology.2023;[Epub] CrossRef
Interest and Satisfaction of Telemedicine Use Among Ambulatory Neurology Patients in Western North Carolina During the COVID-19 Pandemic
K. Alexander Soltany, Reyna Segovia Molina, Carly Pappo, Sharon Thomson, Kelly Pring, Siobhan Cox, Rebecca Merrill, Emily Fishman, Alexander Ambrosini, Gabby Bognet, Kristen Dodenhoff, Heidi Munger Clary, Lauren Strauss, Rachel Graham, Amy K. Guzik, Roy E
Telemedicine and e-Health.2023;[Epub] CrossRef
Parkinson’s disease patients’ perspective on telephone visits during the COVID-19 pandemic
Marta Magriço, Miguel Serôdio, Rita Ventura, Paulo Bugalho
Journal of Neural Transmission.2023; 130(12): 1547. CrossRef
Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders
Emily Houston, Amanda G. Kennedy, Donna O'Malley, Terry Rabinowitz, Gail L. Rose, James Boyd
Telemedicine and e-Health.2022; 28(3): 295. CrossRef
Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic
Tagore Nakornchai, Elena Conci, Anke Hensiek, J William L Brown
Postgraduate Medical Journal.2022; 98(1161): 533. CrossRef
Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research
B. Y. Valdovinos, J. S. Modica, R. B. Schneider
Current Neurology and Neuroscience Reports.2022; 22(2): 113. CrossRef
Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic
Shadi Ghourchian, Yasar A. Torres-Yaghi, Stuart H. Isaacson, Fernando Pagan, Kelly E. Lyons, Brian James Nagle, Sanskruti Patel, Rajesh Pahwa
Telemedicine and e-Health.2022; 28(11): 1651. CrossRef
Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study
Yaqian Xu, Megan P. Feeney, Matthew Surface, Dan Novak, Michelle S. Troche, James C. Beck, Roy N. Alcalay
Movement Disorders.2022; 37(6): 1289. CrossRef
Service process factors affecting patients’ and clinicians’ experiences on rapid teleconsultation implementation in out-patient neurology services during COVID-19 pandemic: a scoping review
Guangxia Meng, Carrie McAiney, Christopher M. Perlman, Ian McKillop, Therese Tisseverasinghe, Helen H. Chen
BMC Health Services Research.2022;[Epub] CrossRef
Telemedicine in the Management of Parkinson’s Disease: Achievements, Challenges, and Future Perspectives
Esther Cubo, Pedro David Delgado-López
Brain Sciences.2022; 12(12): 1735. CrossRef
Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey
Rimal Bera, Morgan Bron, Betsy Benning, Samantha Cicero, Heintje Calara, Diane Darling, Ericha Franey, Kendra Martello, Charles Yonan
Neuropsychiatric Disease and Treatment.2022; Volume 18: 2945. CrossRef

Case Report

Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia: Emmaline Zantua Fernando, Jeryl Ritzi Tan Yu, Salvador Miclat Abad Santos, Roland Dominic Go Jamora; J Mov Disord. 2021;14(1):75-77. Published online December 7, 2020; DOI: https://doi.org/10.14802/jmd.20091

5,329 View
122 Download
4 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Citations

Citations to this article as recorded by

Safety profile of COVID-19 drugs in a real clinical setting
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
European Journal of Clinical Pharmacology.2022; 78(5): 733. CrossRef
Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo
Vinícius de Mello, Vinícius de Paula Pereira, João Paulo Vilela Rodrigues, Suelem Tavares da Silva Penteado, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo
Revista Panamericana de Salud Pública.2022; 46: 1. CrossRef

Brief communication

Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis: Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal; J Mov Disord. 2020;13(3):218-222. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20073

8,060 View
116 Download
16 Web of Science
5 Crossref

Abstract PDF

Objective
The novel coronavirus disease (COVID-19) pandemic and public health measures to control it have resulted in unique challenges in the management of patients with deep brain stimulation (DBS). We report our experience with the management of acute worsening of symptoms due to battery exhaustion in 3 patients with DBS.
Methods
Patients with DBS for movement disorders who visited the emergency room due to battery exhaustion during the nationwide lockdown from April to May 2020 were included.
Results
Two patients with subthalamic nucleus-DBS for Parkinson’s disease (PD) and one with globus pallidus interna-DBS for generalized dystonia presented with acute worsening of symptoms due to battery exhaustion. Urgent battery replacement was performed in both patients with PD. The patient with generalized dystonia was managed with medication adjustment as he chose to defer battery replacement.
Conclusion
DBS battery replacement can be an emergency. Decisions regarding DBS battery replacement should be individualized during this COVID-19 pandemic.

Citations

Citations to this article as recorded by

Effects of COVID-19 on Synaptic and Neuronal Degeneration
Mohammed S. Alqahtani, Mohamed Abbas, Mohammad Y. Alshahrani, Khulud Alabdullh, Amjad Alqarni, Fawaz F. Alqahtani, Layal K. Jambi, Adnan Alkhayat
Brain Sciences.2023; 13(1): 131. CrossRef
Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy
Vittorio Rispoli, Matías Eduardo Díaz Crescitelli, Francesco Cavallieri, Francesca Antonelli, Stefano Meletti, Luca Ghirotto, Franco Valzania
Frontiers in Neurology.2022;[Epub] CrossRef
Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
Parkinsonism & Related Disorders.2021; 87: 39. CrossRef
An Investigation Into Miniaturised Closed-Loop DBS Devices
Dean M. Corva, Scott D. Adams, Kevin E. Bennet, Parastoo Hashemi, Michael Berk, Abbas Z. Kouzani
IEEE Transactions on Medical Robotics and Bionics.2021; 3(3): 671. CrossRef
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
Frontiers in Neurology.2020;[Epub] CrossRef

Review Article

COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson’s Disease Patient Care: Roongroj Bhidayasiri, Sasivimol Virameteekul, Jong-Min Kim, Pramod Kr. Pal, Sun-Ju Chung; J Mov Disord. 2020;13(2):105-114. Published online April 30, 2020; DOI: https://doi.org/10.14802/jmd.20042

20,653 View
760 Download
59 Web of Science
55 Crossref

Abstract PDF

While many infectious disorders are unknown to most neurologists, COVID-19 is very different. It has impacted neurologists and other health care workers, not only in our professional lives but also through the fear and panic within our own families, colleagues, patients and their families, and even in the wider public. COVID-19 affects all sorts of individuals, but the elderly with underlying chronic conditions are particularly at risk of severe disease, or even death. Parkinson’s disease (PD) shares a common profile as an age-dependent degenerative disorder, frequently associated with comorbidities, particularly cardiovascular diseases, so PD patients will almost certainly fall into the high-risk group. Therefore, the aim of this review is to explore the risk of COVID-19 in PD based on the susceptibility to severe disease, its impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak, where neurologists face various challenges on how we can maintain effective care for PD patients without exposing them, or ourselves, to the risk of infection. It is less than six months since the identification of the original COVID-19 case on New Year’s Eve 2019, so it is still too early to fully understand the natural history of COVID-19 and the evidence on COVID-19-related PD is scant. Though the possibilities presented are speculative, they are theory-based, and supported by prior evidence from other neurotrophic viruses closely related to SARS-CoV-2. Neurologists should be on high alert and vigilant for potential acute and chronic complications when encountering PD patients who are suspected of having COVID-19.

Citations

Citations to this article as recorded by

Covid-19 in Parkinson's Disease treated by drugs or brain stimulation
M. Salari, M. Etemadifar, A. Zali, Z. Aminzade, I. Navalpotro-Gomez, S. Tehrani Fateh
Neurología.2024; 39(3): 254. CrossRef
Calidad de vida de las personas con enfermedad de Parkinson durante el confinamiento por la pandemia por covid-19
A.M. Fernández-Elgueta, H.F. Retamal-Matus, C. Núñez-Espinosa, P. Barria Aburto
Rehabilitación.2024; 58(1): 100821. CrossRef
Efficacy of non-immersive virtual reality-based telerehabilitation on postural stability in Parkinson's disease: a multicenter randomized controlled trial
Michela GOFFREDO, Francesca BAGLIO, Roberto DE ICCO, Stefania PROIETTI, Giorgio MAGGIONI, Andrea TUROLLA, Sanaz POURNAJAF, Johanna JONSDOTTIR, Federica ZENI, Sara FEDERICO, Luisa CACCIANTE, Matteo CIOETA, Cristina TASSORELLI, Marco FRANCESCHINI, Rocco S.
European Journal of Physical and Rehabilitation Medicine.2024;[Epub] CrossRef
Covid-19 in Parkinson's Disease treated by drugs or brain stimulation
M. Salari, M. Etemadifar, A. Zali, Z. Aminzade, I. Navalpotro-Gomez, S. Tehrani Fateh
Neurología (English Edition).2024; 39(3): 254. CrossRef
COVID-19 and Parkinson’s disease: a systematic review and meta-analysis
Maryam Afraie, Ghobad Moradi, Pardis Mohammadzedeh, Mobin Azami, Sevda Riyahifar, Yousef Moradi
Acta Neurologica Belgica.2023; 123(4): 1209. CrossRef
Survey on the Impact of the COVID-19 Pandemic on Patients with Parkinson’s Disease and Their Caregivers in Japan
Nobutaka Hattori, Yoshiko Okada, Yayoi Kawata, Yoshihiko Furusawa, Takumi Imai, Hisako Yoshida, Mihoko Ota, Masaki Arai, Ayumi Shintani, Jovelle Fernandez
Patient Preference and Adherence.2023; Volume 17: 1221. CrossRef
COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection
Salvatore Iacono, Giuseppe Schirò, Chiara Davì, Sergio Mastrilli, Michelle Abbott, Fabrizio Guajana, Valentina Arnao, Paolo Aridon, Paolo Ragonese, Cesare Gagliardo, Claudia Colomba, Nicola Scichilone, Marco D’Amelio
Frontiers in Neurology.2023;[Epub] CrossRef
Worsening of Parkinson’s Disease After Termination of COVID-19 Quarantine Cannot Be Reversed Despite Resumption of Physiotherapy
Christian Ineichen, Heide Vogel-Baumann, Matthias Sitzler, Günther Deuschl, Christian R. Baumann
Journal of Parkinson's Disease.2023; 13(5): 845. CrossRef
The Impact of COVID-19 on Parkinson’s Disease: A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients’ Perceptions
Gustav Cedergren Weber, Jonathan Timpka, Filip Bergquist, David Bäckström, Nil Dizdar, Karin Gunnarsson, Dag Nyholm, Per Svenningsson, Per Odin, Gessica Sala
Acta Neurologica Scandinavica.2023; 2023: 1. CrossRef
Remote Assessment of Parkinson’s Disease Patients Amidst the COVID-19 Lockdown in Mexico
Rodrigo León-García, Emmanuel Ortega-Robles, Oscar Arias-Carrión
Brain Sciences.2023; 13(7): 1114. CrossRef
Social and economic development impact of elderly health care products based on design ethics
Na Qi, Xun Zhang, Muhammad Attique Khan, Gaurav Dhiman, Sathishkumar VE
Intelligent Data Analysis.2023; 27: 137. CrossRef
The effects of an individualized smartphone-based exercise program on self-defined motor tasks in Parkinson’s disease: a long-term feasibility study
Lisa Lützow, Isabelle Teckenburg, Veronika Koch, Franz Marxreiter, Jelena Jukic, Sabine Stallforth, Martin Regensburger, Jürgen Winkler, Jochen Klucken, Heiko Gaßner
Journal of Patient-Reported Outcomes.2023;[Epub] CrossRef
Doctor Hope; Calming and Comforting Loneliness in Parkinson’s Disease
Sasivimol Virameteekul, Roongroj Bhidayasiri
Clinical Parkinsonism & Related Disorders.2022; 6: 100131. CrossRef
Neurological toll of COVID-19
Shivam Bhola, Jhillika Trisal, Vikram Thakur, Parneet Kaur, Saurabh Kulshrestha, Shashi Kant Bhatia, Pradeep Kumar
Neurological Sciences.2022; 43(4): 2171. CrossRef
Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic
Roberto Erro, Sofia Cuoco, Emanuele Nigro, Raffaele Ragone, Paolo Barone
Journal of Movement Disorders.2022; 15(1): 77. CrossRef
Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer’s and Parkinson’s Disease
Ankita Sood, Ravi Goyal, Harshdeep Singh, Tapan Behl, Sandeep Arora, Balraj Saini, Rajwinder Kaur
CNS & Neurological Disorders - Drug Targets.2022; 21(3): 235. CrossRef
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design
Konrad Rejdak, Piotr Fiedor, Robert Bonek, Aleksander Goch, Agnieszka Gala-Błądzińska, Waldemar Chełstowski, Jacek Łukasiak, Sławomir Kiciak, Piotr Dąbrowski, Mateusz Dec, Zbigniew J. Król, Ewa Papuć, Adriana Zasybska, Agnieszka Segiet, Paweł Grieb
Contemporary Clinical Trials.2022; 116: 106755. CrossRef
Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
Jaime Silva, Felipe Patricio, Aleidy Patricio-Martínez, Gerardo Santos-López, Lilia Cedillo, Yousef Tizabi, Ilhuicamina Daniel Limón
Frontiers in Neuroscience.2022;[Epub] CrossRef
Online dance classes during the Covid-19 pandemic: new challenges and teaching strategies for the ‘Dance & Parkinson’s at home’ project
Marcela Dos Santos Delabary, Isadora Loch Sbeghen, Mariana Wolffenbuttel, Djefri Ramon Pereira, Aline Nogueira Haas
Research in Dance Education.2022; : 1. CrossRef
Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia
Maria Antonietta Barbieri, Gianluca Bagnato, Carmelo Ioppolo, Antonio Giovanni Versace, Natasha Irrera
CNS & Neurological Disorders - Drug Targets.2022; 21(10): 1017. CrossRef
Factors Related to Experiencing Pain in Patients Affected by Chronic Inflammatory Rheumatic Disease During the COVID-19 Pandemic
Tfarah El Joumani, Hanan Rkain, Fatima Zahrae Taik, Kenza Hassouni, Redouane Abouqal, Sara Bahloul, Nada Alami, Latifa Tahiri, Najia Hajjaj-Hassouni, Fadoua Allali
The Open Pain Journal.2022;[Epub] CrossRef
A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study
Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova
Neurology, Neuropsychiatry, Psychosomatics.2022; 14(6): 40. CrossRef
Attitudes toward telemedicine of patients with Parkinson’s disease during the COVID‐19 pandemic
Kanako Kurihara, Koichi Nagaki, Kotoe Inoue, Sumiko Yamamoto, Takayasu Mishima, Shinsuke Fujioka, Shinji Ouma, Yoshio Tsuboi
Neurology and Clinical Neuroscience.2021; 9(1): 77. CrossRef
Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism
Luca Vignatelli, Corrado Zenesini, Laura M.B. Belotti, Elisa Baldin, Giuseppe Bonavina, Giovanna Calandra‐Buonaura, Pietro Cortelli, Carlo Descovich, Giovanni Fabbri, Giulia Giannini, Maria Guarino, Roberta Pantieri, Giuseppe Samoggia, Cesa Scaglione, Sus
Movement Disorders.2021; 36(1): 1. CrossRef
Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates
Roberta Eduarda Grolli, Maiqueli Eduarda Dama Mingoti, Amanda Gollo Bertollo, Adriana Remião Luzardo, João Quevedo, Gislaine Zilli Réus, Zuleide Maria Ignácio
Molecular Neurobiology.2021; 58(5): 1905. CrossRef
COVID-19: Implications for Sudden Death in Parkinson’s Disease
Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza
Journal of Movement Disorders.2021; 14(1): 78. CrossRef
Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment
Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora
Journal of Movement Disorders.2021; 14(1): 29. CrossRef
COVID-19 in age-related neurodegenerative diseases: is there a role for vitamin D3 as a possible therapeutic strategy?
Milena de Barros Viana, Bárbara dos Anjos Rosário, Maria de Fátima Santana de Nazaré, Débora Estadella, Daniel Araki Ribeiro, Glauce Socorro de Barros Viana
Reviews in the Neurosciences.2021; 32(2): 235. CrossRef
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review
Agnes Langer, Lucia Gassner, Anna Flotz, Sebastian Hasenauer, Jakob Gruber, Laurenz Wizany, Rochus Pokan, Walter Maetzler, Heidemarie Zach
npj Parkinson's Disease.2021;[Epub] CrossRef
Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19
Dipak Kumar, Sadaf Jahan, Andleeb Khan, Arif Jamal Siddiqui, Neeru Singh Redhu, Wahajuddin, Johra Khan, Saeed Banwas, Bader Alshehri, Mohammed Alaidarous
Molecular Neurobiology.2021; 58(7): 3417. CrossRef
Auswirkungen der COVID-19 Pandemie auf die medizinische Versorgung von Patienten mit angeborenen Blutungsneigungen
Martin Olivieri, Susan Halimeh, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Sylvia von Mackensen
Das Gesundheitswesen.2021; 83(04): 282. CrossRef
Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
Parkinsonism & Related Disorders.2021; 87: 39. CrossRef
Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany
Raphael Scherbaum, Eun Hae Kwon, Daniel Richter, Dirk Bartig, Ralf Gold, Christos Krogias, Lars Tönges
Movement Disorders.2021; 36(5): 1049. CrossRef
Chronic pain experience and health inequities during the COVID-19 pandemic in Canada: qualitative findings from the chronic pain & COVID-19 pan-Canadian study
Lise Dassieu, M. Gabrielle Pagé, Anaïs Lacasse, Maude Laflamme, Vickie Perron, Audrée Janelle-Montcalm, Maria Hudspith, Gregg Moor, Kathryn Sutton, James M Thompson, Manon Choinière
International Journal for Equity in Health.2021;[Epub] CrossRef
The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson’s Disease: An Updated Systematic Review
Vikash Jaiswal, Danah Alquraish, Zouina Sarfraz, Azza Sarfraz, Shavy Nagpal, Prakriti Singh Shrestha, Dattatreya Mukherjee, Prathima Guntipalli, Diana F. Sánchez Velazco, Arushee Bhatnagar, Saloni Savani, Elmjedina Halilaj, Samir Ruxmohan, Wilson Cueva
Journal of Primary Care & Community Health.2021; 12: 215013272110397. CrossRef
Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
Takayasu Mishima, Shinsuke Fujioka, Takashi Morishita, Tooru Inoue, Yoshio Tsuboi
Journal of Personalized Medicine.2021; 11(7): 650. CrossRef
Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran
Mehri Salari, Masoud Etemadifar, Farzad Ashrafi, Davood Ommi, Zahra Aminzade, Sepand Tehrani Fateh
Parkinsonism & Related Disorders.2021; 89: 90. CrossRef
COVID-19 social distancing: negative effects on people with Parkinson disease and their associations with confidence for self-management
Galit Yogev-Seligmann, Michal Kafri
BMC Neurology.2021;[Epub] CrossRef
Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination
Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim
Journal of Movement Disorders.2021; 14(3): 177. CrossRef
Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy
Smriti Sinha, Swati Mittal, Rupali Roy
Journal of Movement Disorders.2021; 14(3): 184. CrossRef
Impact of COVID‐19 on Patient Care, Training, and Research in Movement Disorders in MDS‐AOS Region
Shweta Prasad, Hrishikesh Kumar, Roongroj Bhidayasiri, Pramod Kumar Pal
Movement Disorders.2021; 36(11): 2457. CrossRef
Secondary Impact of COVID-19 Pandemic on People with Parkinson’s Disease—Results of a Polish Online Survey
Karolina Krzysztoń, Beata Mielańczuk-Lubecka, Jakub Stolarski, Anna Poznańska, Katarzyna Kępczyńska, Agata Zdrowowicz, Izabela Domitrz, Jan Kochanowski
Brain Sciences.2021; 12(1): 26. CrossRef
Dance as Lifeline: Transforming Means for Engagement and Connection in Times of Social Isolation
Maria Portman Kelly, David Leventhal
Health Promotion Practice.2021; 22(1_suppl): 64S. CrossRef
Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital
Adalberto STUDART-NETO, Bruno Fukelmann GUEDES, Raphael de Luca e TUMA, Antonio Edvan CAMELO FILHO, Gabriel Taricani KUBOTA, Bruno Diógenes IEPSEN, Gabriela Pantaleão MOREIRA, Júlia Chartouni RODRIGUES, Maíra Medeiros Honorato FERRARI, Rafael Bernhart CAR
Arquivos de Neuro-Psiquiatria.2020; 78(8): 494. CrossRef
Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic
Ali Elbeddini, Anthony To, Yasamin Tayefehchamani, Cindy Wen
Journal of Clinical Movement Disorders.2020;[Epub] CrossRef
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
David Sulzer, Angelo Antonini, Valentina Leta, Anna Nordvig, Richard J. Smeyne, James E. Goldman, Osama Al-Dalahmah, Luigi Zecca, Alessandro Sette, Luigi Bubacco, Olimpia Meucci, Elena Moro, Ashley S. Harms, Yaqian Xu, Stanley Fahn, K. Ray Chaudhuri
npj Parkinson's Disease.2020;[Epub] CrossRef
Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson's Disease
Shweta Prasad, VikramVenkappayya Holla, Koti Neeraja, BharathKumar Surisetti, Nitish Kamble, Ravi Yadav, PramodKumar Pal
Neurology India.2020; 68(4): 792. CrossRef
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Ethan G. Brown, Lana M. Chahine, Samuel M. Goldman, Monica Korell, Emerald Mann, Daniel R. Kinel, Vanessa Arnedo, Kenneth L. Marek, Caroline M. Tanner
Journal of Parkinson's Disease.2020; 10(4): 1365. CrossRef
Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany
Sylvia von Mackensen, Susan Halimeh, Manuela Siebert, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Martin Olivieri
Haemophilia.2020;[Epub] CrossRef
Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients
Diego Santos‐García, Mila Oreiro, Patricia Pérez, Gemma Fanjul, Jose Manuel Paz González, María José Feal Painceiras, Carlos Cores Bartolomé, Lorena Valdés Aymerich, Carlos García Sancho, Maria del Mar Castellanos Rodrigo
Movement Disorders.2020; 35(10): 1712. CrossRef
The Impact of COVID‐19 on Access to Parkinson's Disease Medication
Julia Ling‐Yu Cheong, Zhao Hang Keith Goh, Connie Marras, Caroline M. Tanner, Meike Kasten, Alastair J. Noyce
Movement Disorders.2020; 35(12): 2129. CrossRef
Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis
Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal
Journal of Movement Disorders.2020; 13(3): 218. CrossRef
Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center
Joy Antonelle de Marcaida, Jeffrey Lahrmann, Duarte Machado, Lawrence Bluth, Michelle Dagostine, Maria Moro-de Casillas, Elena Bortan, Sulada Kanchana, Mark Alberts
Geriatrics.2020; 5(3): 54. CrossRef
Update on Neurological Manifestations of SARS-CoV-2
Hisham Valiuddin, Almir Kalajdzic, James Rosati, Kevin Boehm, Dominique Hill
Western Journal of Emergency Medicine.2020;[Epub] CrossRef
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
Frontiers in Neurology.2020;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search